Regulatory Proposals - 2023

2023-E ~ Pharmacists Application - the proposal amends Section 501 to remove the requirement to submit an application for initial pharmacist licensure to the Board at least 30 days prior to any examination.

07-18-2023 - Committee scheduled to review and consider Draft #1 .
07-18-2023 - Committee voted to recommend to the Board their approval of Draft #1.
08-16-2023 - Board scheduled to consider the committee recommendation.
08-16-2023 - Board approved the proposal and it became Regulatory Project 2023-11.

2023-D ~ Prescription Monitoring Program (PMP) - the proposal amends the definition of Drugs of Concern in Section 2901 to clarify intent in regard to butalbital containing products and removes naloxone as a drug of concern. It also amends Section 2914 in regards to record retention of PMP information.

07-18-2023 - Committee scheduled to review and consider Draft #1.
07-18-2023 - Committee voted to recommend to the Board their approval of Draft #1.
08-16-2023 - Board scheduled to consider the committee recommendation.
08-16-2023 - Board approved the proposal and it became Regulatory Project 2023-10.

2023-C ~ Automated Medication Systems (AMS) - the proposal amends Section 1217(B) and Section 1509(B) to address the restocking of an AMS.

07-18-2023 - Committee scheduled to review and consider Draft #1 .
07-18-2023 - Committee amended Draft #1 and then voted to recommend to the Board their approval of Draft #2 .
08-01-2023 - Staff subsequently identified additional language in rule requiring amendment and prepared Draft #3 for Board review and consideration.
08-16-2023 - Board scheduled to consider the committee recomendation and the subsequent staff recommendation.
08-16-2023 - Board approved the proposal.
01-24-2024 - Regulation Revision Committee to consider draft proposal (Draft #4) in response to comments received after the August 2023 Board meeting.
04-25-2024 - Committee scheduled to review and consider Draft #5 .
04-25-2024 - Committee developed Draft #6, then voted to recommend to the Board their approval.
05-08-2024 - Board scheduled to consider Draft #6 .
05-08-2024 - Board approved the proposal and it became Regulatory Project 2024-04.

2023-B ~ Product Integrity - the proposal amends Sections 1103 and 2501 to address the environmental conditions where drugs are stored or located to ensure product integrity prior to the transfer of possession to the patient or the patient's agent.

07-18-2023 - Committee scheduled to review and consider Draft #1.
07-18-2023 - Committee voted to recommend to the Board their approval of Draft #1.
08-16-2023 - Board scheduled to consider the committee recommendation.
08-16-2023 - Board approved the proposal and it became Regulatory Project 2023-09.

2023-A ~ DATA-Waiver Registration Elimination - Amends Section 2745 to remove the requirement for a DATA-Waiver registration number in response to the federal Consolidated Appropriations Act of 2023.

01-12-2023 - DEA let ter to registrants regarding the elimnation of the DATA-Waiver Program.
01-18-2023 - Committee reviewed Draft #1, then voted to recommend to the Board their approval.
02-15-2023 - Board approved Draft #1 for promulgation upon the instruction of the President and incorporated into Regulatory Project 2023-08.